Skip to main content
TipRanks
Go Ultimate75% OFF

C-MER Eye Care Holdings Limited (3309) AI Stock Analysis

2 Followers
HK:3309

C-MER Eye Care Holdings Limited

(HKEX:3309)

Select Model
Rating:70Outperform
Price Target:HKD 1.00â–²(2.56% Upside)
Action:reiterated
Date:11/07/26

The score is supported primarily by a strong balance sheet, improving cash generation, and reasonable valuation. Profitability volatility and mixed long-term technical positioning limit the upside, despite positive short-term momentum.

Positive Factors
Strong cash generationConsistently positive operating cash flow and strong free cash flow provide internal funding for clinic expansion, investment, and shareholder returns. The 2025 step-up in free cash flow also suggests improving cash conversion, strengthening financial resilience over the next several quarters.
Negative Factors
Volatile profitabilityRepeated swings between profit and loss make earnings power less predictable and complicate planning for expansion, staffing, and capital allocation. Until profitability is sustained across several reporting periods, the business remains exposed to weaker earnings quality despite the 2025 recovery.

C-MER Eye Care Holdings Limited (3309) vs. iShares MSCI Hong Kong ETF (EWH)

-60%-50%-40%-30%-20%-10%0%10%20%HK:3309-43.80%EWH+8.17%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
HKD 1.16B
Dividend Yield
3.08%
Average Volume (3M)
469.65K
Price to Earnings (P/E)
11.6
Beta (1Y)
0.79
Revenue Growth
4.75%
EPS Growth
―
Country
Hong Kong
Employees
2,200
Sector
Healthcare
Sector Strength
51
Industry
Medical - Care Facilities

C-MER Eye Care Holdings Limited Business Overview & Revenue Model

Company Description

C-MER Medical Holdings Limited specializes in offering both medical treatments and therapeutic services for a variety of eye conditions. Its business activities are segmented into two primary areas: the delivery of ophthalmological services and the r...

C-MER Eye Care Holdings Limited Financial Statement Overview

Summary

Strong balance-sheet stability and improving cash flow support the score, while revenue growth is offset by volatile profitability and inconsistent margins.

Income Statement

65Positive

Balance Sheet

82Very Positive

Cash Flow

75Positive
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue2.03B1.95B1.91B1.92B1.73B1.11B
Gross Profit633.13M603.67M527.62M618.96M365.34M309.44M
EBITDA373.27M341.37M343.30M363.38M194.31M177.80M
Net Income100.44M100.37M-135.16M62.00M-21.88M21.86M
Balance Sheet
Total Assets2.86B2.73B2.72B2.75B2.90B1.96B
Cash, Cash Equivalents and Short-Term Investments563.37M465.96M467.25M557.42M698.51M442.36M
Total Debt433.61M426.78M437.79M362.99M452.49M471.69M
Total Liabilities868.58M796.01M830.24M755.35M903.45M618.63M
Stockholders Equity1.83B1.77B1.75B1.85B1.87B1.33B
Cash Flow
Free Cash Flow323.23M223.94M124.50M245.30M100.63M19.18M
Operating Cash Flow400.23M301.47M283.12M361.15M191.86M148.41M
Investing Cash Flow-45.70M-169.66M-174.72M-245.37M-210.65M-392.72M
Financing Cash Flow-196.81M-212.38M-194.92M-242.88M293.68M85.12M

C-MER Eye Care Holdings Limited Technical Analysis

Technical Analysis SentimentPositive
Last Price0.97

Price Trends

50DMA0.84Positive
100DMA0.88Positive
200DMA1.06Negative

Market Momentum

MACD0.04Negative
RSI66.97Neutral
STOCH76.41Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:3309, the sentiment is Positive. The current price of 0.97 is above the 20-day moving average (MA) of 0.88, above the 50-day MA of 0.84, and below the 200-day MA of 1.06, indicating a neutral trend. The MACD of 0.04 indicates Negative momentum. The RSI at 66.97 is Neutral, neither overbought nor oversold. The STOCH value of 76.41 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:3309.

C-MER Eye Care Holdings Limited Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

HK:3309 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
HK:1526HK:152679OutperformHKD 1.35B3.8317.86%2.35%1.25%12.60%
HK:2219HK:221973OutperformHKD 1.68B8.486.97%10.14%3.85%-1.23%
HK:3309HK:330970OutperformHKD 1.20B11.585.57%3.08%4.75%―
HK:3689HK:368964NeutralHKD 601.91M5.286.35%10.56%-0.27%29.73%
HK:1846HK:184652NeutralHKD 671.52M272.730.20%2.10%20.54%-96.74%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
HK:3886HK:388648NeutralHKD 1.22B86.190.48%1.00%-3.26%―

* Healthcare Sector Average

Performance Comparison

-40%-20%0%20%HK:3309HK:1526HK:1846HK:2219HK:3689HK:3886Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
HK:3309 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
HK:3309C-MER Eye Care Holdings Limited0.97-0.77-44.13%
HK:1526Rici Healthcare Holdings Ltd.0.85-0.11-11.27%
HK:1846EuroEyes International Eye Clinic Limited2.10-1.14-35.25%
HK:2219Chaoju Eye Care Holdings Ltd.2.390.104.14%
HK:3689Guangdong Kanghua Healthcare Co., Ltd. Class H1.800.105.70%
HK:3886Town Health International Medical Group Ltd.0.18-0.08-31.30%

C-MER Eye Care Holdings Limited Corporate Events

C-MER Medical Posts Higher Revenue but Softer Adjusted Profit in First Half of 2026

Aug 25, 2026

C-MER Medical Holdings Limited reported unaudited interim results for the six months ended 30 June 2026, showing revenue of HK$1,024.4 million, up 8.5% year on year. Gross profit rose 10.0% to HK$323.4 million and gross margin improved slightly to 31...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 07, 2026